HNF-3β Inhibitors
The chemical class identified as HNF-3β inhibitors represents a diverse collection of compounds that intricately modulate the function of the HNF-3β transcription factor through targeted interactions with specific cellular pathways. These inhibitors exert their effects by precisely targeting signaling cascades and molecular events that regulate the intricate activity of HNF-3β within cellular contexts. One prominent member of this inhibitor class is Resveratrol (CAS Number: 501-36-0), a polyphenolic compound abundantly found in red grapes. Resveratrol operates as an indirect inhibitor of HNF-3β by intricately modulating the SIRT1/PGC-1α pathway. Upon administration, Resveratrol activates SIRT1, initiating the deacetylation of PGC-1α. This biochemical alteration enhances the interaction between PGC-1α and HNF-3β, ultimately leading to the suppression of HNF-3β transcriptional activity specifically in liver cells. Another compelling compound within the HNF-3β inhibitors class is Niclosamide (CAS Number: 50-65-7), which functions as an indirect inhibitor by specifically targeting the Wnt/β-catenin pathway. Niclosamide exerts its inhibitory effect by disrupting the phosphorylation of LRP6, a critical co-receptor in the Wnt pathway, thereby hindering the nuclear translocation of β-catenin.
Given that the transcriptional activity of HNF-3β is intricately regulated by β-catenin, Niclosamide provides an indirect avenue to attenuate HNF-3β function by interrupting the canonical Wnt signaling cascade. These illustrative examples underscore the specificity and diversity inherent within the HNF-3β inhibitors class, emphasizing the significance of comprehending the nuanced interactions between these chemicals and the intricate cellular pathways that govern HNF-3β function. The intricate interplay between HNF-3β and these inhibitors showcases the multifaceted nature of transcriptional regulation within cellular environments. The specificity of Resveratrol in targeting the SIRT1/PGC-1α pathway and Niclosamide's selectivity in disrupting Wnt/β-catenin signaling highlight the importance of tailored interventions for modulating HNF-3β function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide, an approved anthelmintic drug, indirectly inhibits HNF-3β by targeting the Wnt/β-catenin pathway. It disrupts the phosphorylation of LRP6, a co-receptor in the Wnt pathway, thereby inhibiting β-catenin nuclear translocation. As HNF-3β transcriptional activity is regulated by β-catenin, niclosamide indirectly attenuates HNF-3β function by disrupting the canonical Wnt signaling cascade. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multikinase inhibitor, indirectly hinders HNF-3β through its impact on the RAF/MEK/ERK pathway. By inhibiting RAF kinases, sorafenib disrupts downstream signaling events, including phosphorylation of HNF-3β by ERK. This interference results in reduced HNF-3β transcriptional activity in hepatocellular carcinoma cells, providing an indirect means of inhibiting HNF-3β through the RAF/MEK/ERK cascade. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
LGK974, a porcupine inhibitor targeting the Wnt pathway, indirectly inhibits HNF-3β by disrupting Wnt ligand secretion. By inhibiting porcupine, an acyltransferase essential for Wnt ligand palmitoylation, LGK974 attenuates Wnt signaling, leading to reduced HNF-3β transcriptional activity. This indirect modulation occurs upstream of HNF-3β, providing a unique avenue for interference in the Wnt-dependent regulation of HNF-3β in various cellular contexts. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly affects HNF-3β by suppressing the MEK/ERK pathway. Through inhibition of MEK, trametinib interferes with ERK-mediated phosphorylation events that regulate HNF-3β activity. This indirect modulation disrupts the MEK/ERK/HNF-3β axis, resulting in diminished transcriptional activity of HNF-3β in cancer cells, showcasing the potential for targeted MEK inhibition as an indirect strategy to influence HNF-3β function. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490, a JAK2 inhibitor, indirectly inhibits HNF-3β by modulating the JAK/STAT pathway. By inhibiting JAK2, AG-490 disrupts STAT3 phosphorylation and its subsequent translocation to the nucleus. This interference affects the STAT3/HNF-3β axis, leading to reduced HNF-3β transcriptional activity in inflammatory and oncogenic contexts. AG-490's indirect modulation showcases its potential as a tool for investigating the JAK/STAT-dependent regulation of HNF-3β. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly inhibits HNF-3β by disrupting the PI3K/AKT pathway. Through inhibition of PI3K, LY294002 suppresses AKT activation, influencing downstream signaling events that impact HNF-3β transcriptional activity. This indirect modulation highlights the role of the PI3K/AKT/HNF-3β axis, providing insights into potential therapeutic strategies for conditions where aberrant PI3K signaling contributes to dysregulated HNF-3β function. | ||||||
PI3K/HDAC Inhibitor | 1339928-25-4 | sc-364584 sc-364584A | 5 mg 10 mg | $347.00 $471.00 | ||
CUDC-907, a dual PI3K/HDAC inhibitor, indirectly inhibits HNF-3β by targeting both the PI3K/AKT and HDAC pathways. CUDC-907 inhibits PI3K, leading to reduced AKT activation, while also inhibiting HDACs, altering the acetylation status of histones associated with HNF-3β target genes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an inhibitor of NF-κB activation, indirectly inhibits HNF-3β by disrupting the NF-κB signaling pathway. BAY 11-7082 inhibits IKKβ, a key regulator of NF-κB activation, leading to decreased NF-κB nuclear translocation and subsequent downregulation of HNF-3β target genes. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
AG-879, an ErbB2 inhibitor, indirectly inhibits HNF-3β by targeting the ErbB2/PI3K pathway. By inhibiting ErbB2, AG-879 disrupts downstream signaling events that influence PI3K/AKT activation, impacting the PI3K/AKT/HNF-3β axis. | ||||||